Regen BioPharma, Inc. Provides Update on NR2F6 Small Molecule Optimization Program for Treating Cancer and Arthritis

Thursday, March 23, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

SAN DIEGO, March 23, 2017 /PRNewswire/ --

Analogues Have Been Synthesized for Lead Compounds

and are Complete, now the Optimization Process is set to Begin Utilizing NR2F6 Protein Molecules

Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP), has provided an update on the status of its medicinal chemistry program being conducted by ChemDiv

Inc., for the optimization of its lead compounds, RG-NA01, RG-NA02, RG-NI01 and RG-NI02. These compounds are small molecules and consist of activators (RG-NA01 and RG-NA02) and inhibitors (RG-NI01 and RG-NI02) of NR2F6. They were identified using Regen's patented screening methodology and unique chemical libraries.

ChemDiv Inc., a fully integrated target-to-clinic contract research organization, which is conducting the compound optimization studies for Regen BioPharma, has reported that they have synthesized more than 30 analogues of our initial small molecules and will begin screening them for activity in the coming weeks. Additionally, purified protein that will be used in these studies has been manufactured and received by the Company. Now that this crucial first phase has been completed, the Company can move forward with ChemDiv on the actual optimization process, which involves introducing the synthesized compound analogues to the special NR2F6 protein molecule and cellular systems.

The NR2F6 nuclear receptor has been identified as a potentially significant immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6, in an effort to unleash the cancer-killing potential of a patient's own immune system, as well as identifying agonists, which should suppress the immune system in diseases where the immune system is over-activated, such as rheumatoid arthritis and other autoimmune diseases.

"The optimization process of small molecule development is iterative. It requires a series of compounds to be synthesized and their activity to be understood. By doing this repeatedly and learning about the relationship between structure and activity, optimized compounds are generated," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "We are on track and on schedule. The next two months will be very important as we define the key portions of the structures that relate to activity in the protein molecule."

"This is an extremely exciting time for Regen as we are moving the company dynamically forward. The ChemDiv studies are the gateway to potentially strong relationships, with one or more large pharmaceutical companies that have already express interest in our NR2F6 small molecule therapeutic models for treating cancer and arthritis immunologically. ChemDiv, Inc. is an elite contract research organization and we are enthusiastic about their involvement with our small molecule drug development program," stated David Koos, Ph.D., Chairman & CEO of Regen BioPharma Inc. "Their professionalism and deep knowledge of this space makes it easy for us to oversee this process and allows us to strategically plan next steps."

About ChemDiv Inc.: 

ChemDiv is a fully integrated discovery and development CRO serving the life science industry for 26 years. To date ChemDiv has carried out numerous successful innovative open-access platform collaborations, with Sanofi, Eli Lilly, Novartis and many other pharma and biotech partners. ChemDiv accelerates and enables pharma and biotech R&D programs from research concepts to clinic and market registration, covering the complete range of disciplines in CNS, oncology, inflammation, cardio metabolic, infectious diseases, and other therapeutic areas.

About Regen BioPharma Inc.: 

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on gene silencing therapy and small molecule therapies for treating cancer, along with developing stem cell treatments for aplastic anemia and disorders of the bone marrow. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information Regen BioPharma Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer Phone: +1-619-702-1404 Fax: +1-619-330-2328 E-mail: david.koos@regenbiopharma.com  

For Investor Relations: Synergy: Phone: 1-888-259-9173

http://www.regenbiopharma.com

SOURCE Regen BioPharma, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook